Genesis Banner
Fuel peak focus by day. Recharge your brain by night.

vilazodone VIIBRYD

Class: SPARI/​Phenylpiperazine-2-benzofurancarboxamide
FDA Indications: MDD
Off-Label Use: Anxiety
Prescribing
Forms: 10, 20, 40mg tablet
Dose Range: 20-40 mg/day
Starting: Start with 10 mg qd x7 days, followed by 20 mg qd x7 days, then ↑ to 40 mg qd. Should be taken with food!

NAMI drug fact sheet

Precautions
Contraindications: Concomitant use of MAOIs
Serious Side Effects: Serotonin syndrome; ↑ risk of SI in children and young adults; may impair platelet aggregation; SIADH
Side Effects: headache, diarrhea, nausea, dizziness, insomnia, abnormal dreams, hyperhidrosis, sexual dysfunction
Pharmacodynamics
1° MOA: Serotonin partial agonist and reuptake inhibitor
2° MOA: 5-HT1A receptor partial agonist
Target: SERT, 5HT1A
Pharmacokinetics
t½: 25 (20-30)° TMAX: 4-5°
Substrate of: 3A4; 2D6, 2C19
Inhibits: ∅ ; Induces: ∅
Active Metabolites: ∅
DDIs
  • - DO NOT CO-PRESCRIBE WITH MAOIs (need a 14-day washout period)
  • - 3A4 inhibitors can ↑ levels; likewise, 3A4 inducers can ↓ levels
Misc
  • - AUC ↓ ~50% if not taken with food
  • - preferentially occupies 5HT1A autoreceptor vs the postsynaptic receptor, which has been theorized to accelerate and augment the clinical effects of SSRI
  • - Clinical trials showed significant antidepressant efficacy with an onset of effect in 1 week, unlike other antidepressants
  • - exhibits dose-proportional linear pharmacokinetics
  • - minimal sexual dysfunction
Special Populations

Category C—There are no adequate and well-controlled studies in pregnant women

There are no clinical data regarding the effect on lactation and nursing

There were no pharmacokinetic differences for vilazodone in patients >65

Mild to severe renal impairment does not affect the clearance.

Mild to severe hepatic impairment does not affect the clearance.

References
Applied Clinical Pharmacokinetics And Pharmacodynamics Of Psychopharmacological Agents
Concise Guide To Drug Interaction Principles For Medical Practice
Foye's Principles Of Medicinal Chemistry

Print Page
logo

Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated August 14 2025 21:35:12. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.